Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis

Changyu Zhu, Kyeong Jin Kim, Xiaobo Wang, Alberto Bartolome, Marcela Salomao, Paola Dongiovanni, Marica Meroni, Mark J. Graham, Katherine P. Yates, Anna Mae Diehl, Robert F. Schwabe, Ira Tabas, Luca Valenti, Joel E. Lavine, Utpal B. Pajvani

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Fibrosis is the major determinant of morbidity and mortality in patients with nonalcoholic steatohepatitis (NASH) but has no approved pharmacotherapy in part because of incomplete understanding of its pathogenic mechanisms. Here, we report that hepatocyte Notch activity tracks with disease severity and treatment response in patients with NASH and is similarly increased in a mouse model of diet-induced NASH and liver fibrosis. Hepatocyte-specific Notch loss-of-function mouse models showed attenuated NASH-associated liver fibrosis, demonstrating causality to obesity-induced liver pathology. Conversely, forced activation of hepatocyte Notch induced fibrosis in both chow- and NASH diet-fed mice by increasing Sox9-dependent Osteopontin (Opn) expression and secretion from hepatocytes, which activate resident hepatic stellate cells. In a cross-sectional study, we found that OPN explains the positive correlation between liver Notch activity and fibrosis stage in patients. Further, we developed a Notch inhibitor [Nicastrin antisense oligonucleotide (Ncst ASO)] that reduced fibrosis in NASH diet-fed mice. In summary, these studies demonstrate the pathological role and therapeutic accessibility of the maladaptive hepatocyte Notch response in NASH-associated liver fibrosis.

Original languageEnglish
Article numberat0344
JournalScience Translational Medicine
Volume10
Issue number468
DOIs
Publication statusPublished - Nov 21 2018

Fingerprint

Liver Cirrhosis
Hepatocytes
Fibrosis
Diet
Hepatic Stellate Cells
Osteopontin
Antisense Oligonucleotides
Liver
Non-alcoholic Fatty Liver Disease
Causality
Obesity
Cross-Sectional Studies
Pathology
Morbidity
Drug Therapy
Mortality
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis. / Zhu, Changyu; Kim, Kyeong Jin; Wang, Xiaobo; Bartolome, Alberto; Salomao, Marcela; Dongiovanni, Paola; Meroni, Marica; Graham, Mark J.; Yates, Katherine P.; Diehl, Anna Mae; Schwabe, Robert F.; Tabas, Ira; Valenti, Luca; Lavine, Joel E.; Pajvani, Utpal B.

In: Science Translational Medicine, Vol. 10, No. 468, at0344, 21.11.2018.

Research output: Contribution to journalArticle

Zhu, C, Kim, KJ, Wang, X, Bartolome, A, Salomao, M, Dongiovanni, P, Meroni, M, Graham, MJ, Yates, KP, Diehl, AM, Schwabe, RF, Tabas, I, Valenti, L, Lavine, JE & Pajvani, UB 2018, 'Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis', Science Translational Medicine, vol. 10, no. 468, at0344. https://doi.org/10.1126/scitranslmed.aat0344
Zhu, Changyu ; Kim, Kyeong Jin ; Wang, Xiaobo ; Bartolome, Alberto ; Salomao, Marcela ; Dongiovanni, Paola ; Meroni, Marica ; Graham, Mark J. ; Yates, Katherine P. ; Diehl, Anna Mae ; Schwabe, Robert F. ; Tabas, Ira ; Valenti, Luca ; Lavine, Joel E. ; Pajvani, Utpal B. / Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis. In: Science Translational Medicine. 2018 ; Vol. 10, No. 468.
@article{574cba79c5da41efa9784fc47080c203,
title = "Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis",
abstract = "Fibrosis is the major determinant of morbidity and mortality in patients with nonalcoholic steatohepatitis (NASH) but has no approved pharmacotherapy in part because of incomplete understanding of its pathogenic mechanisms. Here, we report that hepatocyte Notch activity tracks with disease severity and treatment response in patients with NASH and is similarly increased in a mouse model of diet-induced NASH and liver fibrosis. Hepatocyte-specific Notch loss-of-function mouse models showed attenuated NASH-associated liver fibrosis, demonstrating causality to obesity-induced liver pathology. Conversely, forced activation of hepatocyte Notch induced fibrosis in both chow- and NASH diet-fed mice by increasing Sox9-dependent Osteopontin (Opn) expression and secretion from hepatocytes, which activate resident hepatic stellate cells. In a cross-sectional study, we found that OPN explains the positive correlation between liver Notch activity and fibrosis stage in patients. Further, we developed a Notch inhibitor [Nicastrin antisense oligonucleotide (Ncst ASO)] that reduced fibrosis in NASH diet-fed mice. In summary, these studies demonstrate the pathological role and therapeutic accessibility of the maladaptive hepatocyte Notch response in NASH-associated liver fibrosis.",
author = "Changyu Zhu and Kim, {Kyeong Jin} and Xiaobo Wang and Alberto Bartolome and Marcela Salomao and Paola Dongiovanni and Marica Meroni and Graham, {Mark J.} and Yates, {Katherine P.} and Diehl, {Anna Mae} and Schwabe, {Robert F.} and Ira Tabas and Luca Valenti and Lavine, {Joel E.} and Pajvani, {Utpal B.}",
year = "2018",
month = "11",
day = "21",
doi = "10.1126/scitranslmed.aat0344",
language = "English",
volume = "10",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "468",

}

TY - JOUR

T1 - Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis

AU - Zhu, Changyu

AU - Kim, Kyeong Jin

AU - Wang, Xiaobo

AU - Bartolome, Alberto

AU - Salomao, Marcela

AU - Dongiovanni, Paola

AU - Meroni, Marica

AU - Graham, Mark J.

AU - Yates, Katherine P.

AU - Diehl, Anna Mae

AU - Schwabe, Robert F.

AU - Tabas, Ira

AU - Valenti, Luca

AU - Lavine, Joel E.

AU - Pajvani, Utpal B.

PY - 2018/11/21

Y1 - 2018/11/21

N2 - Fibrosis is the major determinant of morbidity and mortality in patients with nonalcoholic steatohepatitis (NASH) but has no approved pharmacotherapy in part because of incomplete understanding of its pathogenic mechanisms. Here, we report that hepatocyte Notch activity tracks with disease severity and treatment response in patients with NASH and is similarly increased in a mouse model of diet-induced NASH and liver fibrosis. Hepatocyte-specific Notch loss-of-function mouse models showed attenuated NASH-associated liver fibrosis, demonstrating causality to obesity-induced liver pathology. Conversely, forced activation of hepatocyte Notch induced fibrosis in both chow- and NASH diet-fed mice by increasing Sox9-dependent Osteopontin (Opn) expression and secretion from hepatocytes, which activate resident hepatic stellate cells. In a cross-sectional study, we found that OPN explains the positive correlation between liver Notch activity and fibrosis stage in patients. Further, we developed a Notch inhibitor [Nicastrin antisense oligonucleotide (Ncst ASO)] that reduced fibrosis in NASH diet-fed mice. In summary, these studies demonstrate the pathological role and therapeutic accessibility of the maladaptive hepatocyte Notch response in NASH-associated liver fibrosis.

AB - Fibrosis is the major determinant of morbidity and mortality in patients with nonalcoholic steatohepatitis (NASH) but has no approved pharmacotherapy in part because of incomplete understanding of its pathogenic mechanisms. Here, we report that hepatocyte Notch activity tracks with disease severity and treatment response in patients with NASH and is similarly increased in a mouse model of diet-induced NASH and liver fibrosis. Hepatocyte-specific Notch loss-of-function mouse models showed attenuated NASH-associated liver fibrosis, demonstrating causality to obesity-induced liver pathology. Conversely, forced activation of hepatocyte Notch induced fibrosis in both chow- and NASH diet-fed mice by increasing Sox9-dependent Osteopontin (Opn) expression and secretion from hepatocytes, which activate resident hepatic stellate cells. In a cross-sectional study, we found that OPN explains the positive correlation between liver Notch activity and fibrosis stage in patients. Further, we developed a Notch inhibitor [Nicastrin antisense oligonucleotide (Ncst ASO)] that reduced fibrosis in NASH diet-fed mice. In summary, these studies demonstrate the pathological role and therapeutic accessibility of the maladaptive hepatocyte Notch response in NASH-associated liver fibrosis.

UR - http://www.scopus.com/inward/record.url?scp=85056944365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056944365&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aat0344

DO - 10.1126/scitranslmed.aat0344

M3 - Article

C2 - 30463916

AN - SCOPUS:85056944365

VL - 10

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 468

M1 - at0344

ER -